Revolution Medicines Option Alert: Dec 19 $55 Puts at the Bid: 334 vs 1346 OI; Earnings 5/7 After Close [est] 

Revolution Medicines Option Alert: Dec 19 $55 Puts at the Bid: 334 @ $18.3 vs 1346 OI; Earnings 5/7 After Close [est] Ref=$38.02

Revolution Medicines Stock (NASDAQ: RVMD)

Revolution Medicines

REVOLUTION MEDICINES INC

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Healthcare Costs

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ELAN

RVMD

Top 3 Health Care Stocks That Could Blast Off In December

Wall street.Stockmarket.Stock,Traders,Pointing,Highest,Stock,Market,On,Dynamic,Valued,Analysis

Earnings

Equities

Eurozone

Commodities

MOND

NVCR

SMCI

SNTI

UPST

Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates

movers image

BARK

ERAS

FWRD

GRDN

STLA

Stellantis, PG&amp;E And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Revolution Medicines, Inc. - Common Stock

Revolution Medicines Inc

Press Releases

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Revolution Medicines to Participate in March 2025 Investor Conferences

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Health Care

Revolution Medicines to Participate in April 2025 Investor Conferences

ADMA Biologics

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Genmab

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Nuvalent

Vaxcyte

Roivant Sciences

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Comments

Revolution Medicines

Unusual Options Activity for

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga